Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3925-3940

  Hanks, Brent A ^a   Holtzhausen, Alisha ^a   Evans, Katherine S ^a   Jamieson, Rebekah ^a   Gimpel, Petra ^b   Campbell, Olivia M ^a   Hector Greene, Melissa ^a   Sun, Lihong ^c   Tewari, Alok ^a   George, Amanda ^a   Starr, Mark ^a   Nixon, Andrew ^a   Augustine, Christi ^a   Beasley, Georgia ^a   Tyler, Douglas S ^a   Osada, Takayu ^a   Morse, Michael A ^a   Ling, Leona ^c   Lyerly, H Kim ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; CCL22 PROTEIN, MOUSE; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DNA HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MICROARRAY ANALYSIS; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; DOWN REGULATION; EXPERIMENTAL MAMMARY NEOPLASM; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL22; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84883518362     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65745     Document Type: Article

References (58)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol. 2007;25:267-296. (Pubitemid 46697910)
2. Gajewski T, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145. (Pubitemid 44401498)
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998. (Pubitemid 35363648)
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-727. (Pubitemid 44453458)
5. Cochran AJ, Huang R-R, Lee J, Itakura E, Leong SPL, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6(9):659-670. (Pubitemid 44298215)
6. Enk A, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 1997;73(3):309-316. (Pubitemid 27508890)
7. Scarlett UK, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012;209(3):495-506.
8. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFβ.Nat Rev Immunol. 2010;10(8):554-567.
9. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252. (Pubitemid 28155090)
10. Belladonna ML, et al. Cutting edge: autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol. 2008;181(8):5194- 5198.
11. Pallotta MT, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011;12(9):870-878.
12. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762-774. (Pubitemid 39336293)
13. Munn DH, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297(5588):1867-1870. (Pubitemid 35024345)
14. Fallarino F, et al. The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor {zeta}-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752-6761. (Pubitemid 43787857)
15. Sharma MD, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine-2,3-dioxygenase. J Clin Invest. 2007;117(9):2570-2582. (Pubitemid 47494358)
16. Munn DH, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114(2):280-290. (Pubitemid 39071633)
17. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-1154. (Pubitemid 46718399)
18. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949. (Pubitemid 39273735)
19. Gobert M, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000-2009.
20. Blobe GC, et al. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem. 2001;276(27):24627-24637.
21. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human disease. Cell Signal. 2010;22(8):1163-1174.
22. Dong M, et al. The type III TGFbeta receptor suppresses breast cancer progression. J Clin Invest. 2007;117(1):206-217. (Pubitemid 46048467)
23. Finger E, Turley R, Dong M, How T, Fields T, Blobe G. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis. 2008;29(3):528-535. (Pubitemid 351404868)
24. Turley R, Finger E, Hempel N, How T, Fields T, Blobe G. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007;67(3):1090-1098.
25. Mythreye K, Blobe G. The type III TGF-β receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A. 2009;106(20):8221-8226.
26. Gordon K, Dong M, Chislock E, Fields T, Blobe G. Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis. 2008;29(2):252-262. (Pubitemid 351359663)
27. Andres JL, Stanley K, Cheifetz S, Massague J. Membrane-anchored and soluble forms of beta-glycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol. 1989;109(6 pt 1):3137-3145. (Pubitemid 20011937)
28. Lopez-Casillas F, Payne H, Andres J, Massague J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol. 1994;124(4):557-568. (Pubitemid 24064466)
29. Javelaud D, Alexaki V-I, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 2008;21(2):123-132. (Pubitemid 351551229)
30. Lasfar A, Cohen-Solal KA. Resistance to transforming growth factor beta-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis. 2010;31(10):1710-1717.
31. Arteaga C. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993;92(6):2569-2576. (Pubitemid 24006519)
32. Vulcano M, et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol. 2001;31(3):812-822. (Pubitemid 32241777)
33. Bonecchi R, et al. Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. Blood. 1998;92(8):2668-2671. (Pubitemid 28469077)
34. Laouar Y, Sutterwala F, Gorelik L, Flavell R. Transforming growth factor-beta controls T helper type I cell development through regulatoin of natural killer cell interferon-gamma. Nat Immunol. 2005;6(6):600-607. (Pubitemid 41710731)
35. Laouar Y, et al. TGF-β signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105(31):10865-10870.
36. Lievens D, et al. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis [published online ahead of print May 21, 2012]. Eur Heart J. doi:10.1093/eurheartj/ehs106.
37. Morse MA, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer. 2010;126(12):2893-2903.
38. Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007;67(5):2351-2359. (Pubitemid 46424257)
39. Kim S, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res. 2008;68(24):10247-10256.
40. Hartman ZC, et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res. 2010;16(5):1466-1477.
41. Hanks BA, Morse MA. Pharmacological inhibition of TGFbeta as a strategy to augment the antitumor immune response. Curr Opin Investig Drugs. 2010;11(12):1342-1353.
42. Augustine CK, et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther. 2010;9(4):779-790.
43. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148. (Pubitemid 39094044)
44. Fallarino F, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206-1212. (Pubitemid 37547898)
45. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164(7):3596-3599. (Pubitemid 30169812)
46. Grohmann U, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3(11):1097-1101. (Pubitemid 35363664)
47. Yang P, et al. TGF-β- miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291-303.
48. Ramalingam R, et al. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J Immunol. 2012;189(8):3878-3893.
49. Kirkbride KC, Blobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther. 2003;3(2):251-261. (Pubitemid 36458757)
50. Anderton MJ, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39(6):916-924.
51. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs. 2003;21(1):21-32. (Pubitemid 36628482)
52. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399-1405.
53. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006- 4016.
54. Inaba K, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
55. Brawand P, Fitzpatrick DR, Greenfield BW, Brasel K, Maliszewski CR, De Smedt T. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol. 2002;169(12):6711-6719. (Pubitemid 36899255)
56. Rhodes DR, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6. (Pubitemid 38391943)
57. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106(7):2375-2381. (Pubitemid 41510810)
58. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.